162 The IRAP (International Registry of Anakinra for Pericarditis) study confirmed the safety and efficacy of anakinra in treating recurrent pericarditis in a real-world population from 14 specialized pericardial disease referral centers
In STEP trials, patients taking a 7 mg dose of Rybelsus experienced an average of 8.9% weight loss over 68 weeks, compared to 1.8% in the placebo group
In the country, approximately 18% of the population are on GLP-1s, according to doctors
Brand-name Wegovy costs many patients well over $1,000 per month out of pocket, and the promise of a cheaper version feels tantalizingly close
did not find any significant changes of renin, aldosterone, and urinary angiotensinogen after a single GLP-1 infusion in healthy men 28 and the same result was reported in patients with diabetes without kidney function impairment 32